Bone marrow mesenchymal stem cells to ameliorate experimental autoimmune encephalomyelitis via modifying expression patterns of miRNAs

Haghmorad, Dariush; Khaleghian, Ali; Eslami, Majid; Sadeghnejad, Abdolvahid; Tarahomi, Mahdieh; Yousefi, Bahman

doi:10.1007/s11033-023-08843-1

Cited by 8 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, EAE mice injected with placental EVs showed a decrease in T cell proliferation, increase Treg cell, and a subsequent decrease in inflammation adding weight to these findings [ 101 , 102 ]. The same effects were observed in EVs produced from bone marrow, periodontal ligament cells, adipose tissue, and umbilical cord mesenchyme, which raised the levels of protective cytokines, such as IL10, transforming growth factor-beta (TGF-β), and stromal cell-derived factor 1 alpha (SDF-1α), but reduced pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and NALP-3 [ 94 , 96 , 103 - 109 ].…”

Section: Extracellular Vesicles As the Potential Treatment Strategies...mentioning

confidence: 85%

Possible Roles of Extracellular Vesicles in the Pathogenesis and Interventions of Immune-Mediated Central Demyelinating Diseases

Teekaput,

Thiankhaw,

Chattipakorn

et al. 2024

Exp Neurobiol

View full text Add to dashboard Cite

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) are two of the most devastating immune-mediated central demyelinating disorders. NMOSD was once considered as a variant of MS until the discovery of an antibody specific to the condition. Despite both MS and NMOSD being considered central demyelinating disorders, their pathogenesis and clinical manifestations are distinct, however the exact mechanisms associated with each disease remain unclear. Extracellular vesicles (EVs) are nano-sized vesicles originating in various cells which serve as intercellular communicators. There is a large body of evidence to show the possible roles of EVs in the pathogenesis of several diseases, including the immune-mediated central demyelinating disorders. Various types of EVs are found across disease stages and could potentially be used as a surrogate marker, as well as acting by carrying a cargo of biochemical molecules. The possibility for EVs to be used as a next-generation targeted treatment for the immune-mediated central demyelinating disorders has been investigated. The aim of this review was to comprehensively identify, compile and discuss key findings from in vitro , in vivo and clinical studies. A summary of all findings shows that: 1) the EV profiles of MS and NMOSD differ from those of healthy individuals, 2) the use of EV markers as liquid biopsy diagnostic tools appears to be promising biomarkers for both MS and NMOSD, and 3) EVs are being studied as a potential targeted therapy for MS and NMOSD. Any controversial findings are also discussed in this review.

show abstract

Section: Extracellular Vesicles As the Potential Treatment Strategies...mentioning

confidence: 85%

Possible Roles of Extracellular Vesicles in the Pathogenesis and Interventions of Immune-Mediated Central Demyelinating Diseases

Teekaput,

Thiankhaw,

Chattipakorn

et al. 2024

Exp Neurobiol

View full text Add to dashboard Cite

show abstract

“…These include the induction of regulatory T cells while suppressing pathogenic Th1/Th17 phenotypes, upregulation of suppressive and regulatory cytokines such as TGF-β and IL-10, as well as the release of exosome miRNAs such as miR-let7. Simultaneously, inflammatory molecules such as IL-17 and IFN-γ are downregulated [54]. Intriguingly, in vitro studies using human peripheral blood CD4+ T cells from Parkinson's disease patients have indicated that MSCs can induce a shift towards regulatory T cells and suppress Th17 responses, possibly mediated through direct cell-to-cell contact [55].…”

Section: Immunomodulation Of the Adaptive Immune System In Msmentioning

confidence: 99%

The Therapeutic Mechanisms of Mesenchymal Stem Cells in MS—A Review Focusing on Neuroprotective Properties

Gavasso,

Kråkenes,

Olsen

et al. 2024

IJMS

View full text Add to dashboard Cite

In multiple sclerosis (MS), there is a great need for treatment with the ability to suppress compartmentalized inflammation within the central nervous system (CNS) and to promote remyelination and regeneration. Mesenchymal stem cells (MSCs) represent a promising therapeutic option, as they have been shown to migrate to the site of CNS injury and exert neuroprotective properties, including immunomodulation, neurotrophic factor secretion, and endogenous neural stem cell stimulation. This review summarizes the current understanding of the underlying neuroprotective mechanisms and discusses the translation of MSC transplantation and their derivatives from pre-clinical demyelinating models to clinical trials with MS patients.

show abstract

“…Furthermore, miRNAs are noncoding RNA sequences with approximately 18–22 base pairs in length [ 13 ], which can regulate the progression of bone diseases (including OP) [ 14 ]. Dysregulation of miRNAs can lead to the occurrence of multiple diseases (e.g., malignant tumors and inflammation) [ 15 , 16 ]; more importantly, miRNAs are reported to participate in the physiopathology, diagnosis, and therapeutic challenge of OP [ 14 ]. As an important component of epigenetic modification, miRNAs are involved in ontogeny and bone and joint diseases.…”

Section: Introductionmentioning

confidence: 99%

SP1 regulates BMSC osteogenic differentiation through the miR-133a-3p/MAPK3 axis

Zhong,

Sun,

Wang

et al. 2024

J Orthop Surg Res

View full text Add to dashboard Cite

Background The progression of osteoporosis (OP) can dramatically increase the risk of fractures, which seriously disturb the life of elderly individuals. Specific protein 1 (SP1) is involved in OP progression. However, the mechanism by which SP1 regulates OP progression remains unclear. Objective This study investigated the mechanism underlying the function of SP1 in OP. Methods SAMP6 mice were used to establish an in vivo model of age-dependent OP, and BALB/c mice were used as controls. BMSCs were extracted from two subtypes of mice. Hematoxylin and eosin staining were performed to mark the intramedullary trabecular bone structure to evaluate histological changes. ChIP assay was used to assess the targeted regulation between SP1 and miR-133a-3p. The binding sites between MAPK3 and miR-133a-3p were verified using a dual-luciferase reporter assay. The mRNA levels of miR-133a-3p and MAPK3 were detected using quantitative reverse transcription polymerase chain reaction (RT-qPCR). The protein expression of SP1, MAPK3, Colla1, OCN, and Runx2 was examined using Western blotting. Alkaline phosphatase (ALP) kit and Alizarin Red S staining were used to investigate ALP activity and mineralized nodules, respectively. Results The levels of SP1 and miR-133a-3p were upregulated, whereas the expression of MAPK3 was downregulated in BMSCs from SAMP6 mice, and miR-133a-3p inhibitor accelerated osteogenic differentiation in BMSCs. SP1 directly targeted miR-133a-3p, and MAPK3 was the downstream mRNA of miR-133a-3p. Mechanically, SP1 accelerated osteogenic differentiation in BMSCs via transcriptional mediation of the miR-133a-3p/MAPK3 axis. Conclusion SP1 regulates osteogenic differentiation by mediating the miR-133a-3p/MAPK3 axis, which would shed new light on strategies for treating senile OP.

show abstract

Bone marrow mesenchymal stem cells to ameliorate experimental autoimmune encephalomyelitis via modifying expression patterns of miRNAs

Cited by 8 publications

References 50 publications

Possible Roles of Extracellular Vesicles in the Pathogenesis and Interventions of Immune-Mediated Central Demyelinating Diseases

Possible Roles of Extracellular Vesicles in the Pathogenesis and Interventions of Immune-Mediated Central Demyelinating Diseases

The Therapeutic Mechanisms of Mesenchymal Stem Cells in MS—A Review Focusing on Neuroprotective Properties

SP1 regulates BMSC osteogenic differentiation through the miR-133a-3p/MAPK3 axis

Contact Info

Product

Resources

About